New CAR T-Cell therapy KITE-753 takes on axi-cel in lymphoma showdown
Disease control
Not yet recruiting
This study tests a new treatment called KITE-753 against an approved CAR T-cell therapy (axi-cel) in adults with large B-cell lymphoma that came back or didn't respond after initial treatment. About 550 participants will be randomly assigned to receive one of the two therapies. T…
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC